28 SEPTEMBER 2026

NORTHERN 3 VCT PLC

TRANSACTION IN OWN SHARES 

Northern 3 VCT PLC (“the Company”) announces that on 25 September 2026 it purchased for cancellation under an existing authority granted by shareholders 1,145,021 ordinary shares of 5p each in the market at a price of 81.70p per share, representing approximately 0.65% of the Company’s issued ordinary share capital. There remain 175,856,561 ordinary shares in issue. 

In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), the Company notifies the market that the capital of the Company consists of 175,856,561 ordinary shares with a nominal value of 5p each. All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 175,856,561 (“the Figure”). The Figure may be used by a shareholder or other person as the denominator for the calculations by which they will determine if they are required to notify the voting rights they hold in relation to the Company, or a change to those voting rights, under the DTRs. 

Enquiries:

Sarah Williams / James Sly, Mercia Fund Management Limited – 0330 223 1430

Website: www.mercia.co.uk/vcts

Neither the contents of the Mercia Asset Management PLC website, nor the contents of any website accessible from hyperlinks on the Mercia Asset Management PLC website (or any other website), are incorporated into, or form part of, this announcement.

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Siris to acquire Active Ownership’s 19.1% stake in Agfa-Gevaert NV

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV today announced that Siris Capital Group (together with its affiliates, “Siris”) has signed a strategic investment in Agfa-Gevaert NV, to acquire a 19.1% stake currently held by Active Ownership. Terms of the transaction were not disclosed.

The transaction is subject to the closing of the previously announced agreement to combine Agfa’s Digital Printing Solutions business (“Agfa DPS”) with Electronics for Imaging, Inc. (“EFI”), a Siris portfolio company, which in turn is subject to customary regulatory approvals and closing conditions.

Frank Baker, Co-Founder and Managing Partner of Siris, said: “Agfa is a company with nearly 160 years of history, differentiated technical expertise and leading positions across attractive end markets. Through our work with the Agfa team on the EFI-Agfa DPS combination, we have gained an even deeper appreciation for the strength of the business, the quality of its people and the significant opportunities ahead. We are excited to deepen our partnership with Agfa and to serve as a constructive shareholder as the company continues to invest in its growth businesses and build on the transformation underway across the company.”

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

About Siris
Siris is a leading private equity firm focused on control investments in services businesses that enable transformative technologies to scale. The firm invests in companies that support the underlying infrastructure for these technologies and help enterprises integrate them into critical operational workflows. Based in West Palm Beach, Florida, Siris has deployed more than $9 billion of equity capital since inception. www.siris.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Siris to acquire Active Ownership’s 19.1% stake in Agfa-Gevaert NV

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV today announced that Siris Capital Group (together with its affiliates, “Siris”) has signed a strategic investment in Agfa-Gevaert NV, to acquire a 19.1% stake currently held by Active Ownership. Terms of the transaction were not disclosed.

The transaction is subject to the closing of the previously announced agreement to combine Agfa’s Digital Printing Solutions business (“Agfa DPS”) with Electronics for Imaging, Inc. (“EFI”), a Siris portfolio company, which in turn is subject to customary regulatory approvals and closing conditions.

Frank Baker, Co-Founder and Managing Partner of Siris, said: “Agfa is a company with nearly 160 years of history, differentiated technical expertise and leading positions across attractive end markets. Through our work with the Agfa team on the EFI-Agfa DPS combination, we have gained an even deeper appreciation for the strength of the business, the quality of its people and the significant opportunities ahead. We are excited to deepen our partnership with Agfa and to serve as a constructive shareholder as the company continues to invest in its growth businesses and build on the transformation underway across the company.”

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

About Siris
Siris is a leading private equity firm focused on control investments in services businesses that enable transformative technologies to scale. The firm invests in companies that support the underlying infrastructure for these technologies and help enterprises integrate them into critical operational workflows. Based in West Palm Beach, Florida, Siris has deployed more than $9 billion of equity capital since inception. www.siris.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

EFI and Agfa’s DPS Business to Combine and Form a Global, Full-Service Industrial Inkjet Company

Combination to Create a Broader, More Diversified Business with a Comprehensive Product Portfolio, Expanded Geographic Reach and Enhanced Capabilities to Serve Customers Across Key End Markets

Mortsel, Belgium and Londonderry, N.H. – September 28, 2026 – 7.45 a.m. CET

Electronics for Imaging, Inc. (“EFI”), a leading industrial inkjet business and portfolio company of Siris, and Agfa-Gevaert (“Agfa”) today announced a definitive agreement to combine Agfa’s Digital Printing Solutions business (“Agfa DPS”) with EFI. An affiliate of Siris will hold a 60% interest and Agfa will hold a 40% interest in the jointly held company, which will bring together the operating capabilities of EFI and Agfa DPS under a governance structure whereby Siris and Agfa will act as equal partners.

The agreement follows the global partnership EFI and Agfa established in 2024, which enabled both companies to expand their product offerings through access to complementary technologies, underscoring the value that their respective strengths, application expertise and expanded portfolios could create for customers worldwide.

The combination brings together two leading businesses with specialized technology capabilities and application focus areas to create a scaled industrial inkjet business with breadth across the fastest-growing segments of the industry. Backed by a global service network, the combined company will draw on a broader base of inkjet expertise spanning print engines, inks, software and workflow, shortening the path from development to production for customers.

EFI brings global leadership in industrial inkjet, helping customers accelerate the transition from analog to digital imaging, with particular strength in digital single pass for corrugated packaging, roll-to-roll, hybrid and textile printers through its Nozomi, VUTEK and Reggiani platforms. Agfa DPS is a leading provider of industrial inkjet solutions, with distinct strengths in display graphics, décor and packaging applications. Its recently renewed portfolio includes the Jeti TAURO, Onset PANTHERA and SpeedSet ORCA platforms. Together, EFI and Agfa DPS expect to generate approximately €540 million ($625 million) of revenue in 2026 on a pro forma basis and will serve a diversified base of thousands of customers across more than 100 countries, supported by complementary geographic strengths across North America and Europe and a global sales and service network.

The combined company is expected to have the potential to realize significant synergies over time, driven by enhanced cross-selling opportunities and the benefits of a platform with greater scale, including expanded access to new applications and geographies.

“Today’s announcement reflects our long-term commitment to digital printing and our conviction in the future of the industry,” said Pascal Juéry, CEO of Agfa-Gevaert. “By bringing together Agfa DPS and EFI, we are creating a stronger business with greater scale, broader access and enhanced innovation capabilities. Rather than continue as a standalone business, we are choosing to partner with Siris to unlock the next phase of accelerated growth for our DPS business while maintaining meaningful upside for Agfa’s stakeholders.”

“Since our investment in EFI in 2019, we have supported the company’s evolution into a focused industrial inkjet leader, drawing on our experience helping technology and industrial businesses scale,” said Frank Baker, Co-Founder and Managing Partner, and David Calamai, Managing Director, of Siris. “EFI and Agfa DPS bring together distinct and complementary capabilities, forming a business with the reach and depth to do more for customers across more markets. We look forward to partnering with Agfa to accelerate innovation and expansion for customers worldwide.”

“At Agfa, we believe this combination can help accelerate the adoption of digital printing across the industry,” said Vincent Wille, President of Agfa DPS. “By combining technology leadership, global reach and deep application expertise, we can help our customers achieve new levels of productivity, agility and sustainable growth, enabling them to innovate faster, reduce waste and create lasting value across the entire print ecosystem.”

“Our partnership with Agfa over the past two years has highlighted the strength of our complementary technologies, expertise and teams,” said Frank Pennisi, CEO of EFI. “This combination is a natural next step that allows us to build on that momentum with a broader platform, accelerating innovation and expanding the solutions we can deliver to customers across industrial inkjet.”

The proposed transaction is expected to close by the end of 2026 and is subject to customary employee information and consultation processes, regulatory approvals and closing conditions.

EFI and Siris were advised by DC Advisory, which acted as exclusive financial advisor, and Sidley Austin LLP, which served as legal advisor.

About EFI
EFI™ is a global technology company focused on advancing the transformation from analog to digital imaging. The company has a scalable portfolio of products, solutions, services and support for the manufacturing of signage, packaging, textiles and other industrial printing applications. EFI’s offerings include a wide range of printers, inks, digital front ends and workflow software designed to help customers increase profits, improve productivity and optimize production workflows. www.efi.com

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of €1.1 billion. Through its Digital Printing Solutions (DPS) business unit, Agfa provides cutting-edge inkjet printing solutions—equipment, consumables, software and services—designed for high-quality, efficient production in the sign & display and packaging market, as well as a broad range of industrial markets. www.agfa.com

About Siris
Siris is a leading private equity firm focused on control investments in services businesses that enable transformative technologies to scale. The firm invests in companies that support the underlying infrastructure for these technologies and help enterprises integrate them into critical operational workflows. Based in West Palm Beach, Florida, Siris has deployed more than $9 billion of equity capital since inception. www.siris.com

Contact:
EFI
Holly O’Rourke
Corporate Communications
+1 (603)-475-9244
e-mail: holly.orourke@efi.com

Agfa-Gevaert
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Siris
Kate Kelley / Madeline Jones / Woomi Yun
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
e-mail: Siris-JF@joelefrank.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the proposed combination of Electronics for Imaging, Inc. (“EFI”) and Agfa-Gevaert’s Digital Printing Solutions business (“Agfa DPS”), the anticipated timing of completion of the transaction, including the expectation that it will close by the end of 2026, expected synergies and other benefits of the transaction, and the future operations, business prospects, financial performance and performance of the combined company. Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “will,” “may,” “could,” “should,” “would,” “potential” and similar expressions.

These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results and developments to differ materially. Such risks and uncertainties include, among others, the ability to obtain required regulatory approvals; the completion of customary employee information and consultation processes; the satisfaction of other closing conditions; the possibility that the transaction may be delayed or not completed on the anticipated terms or timeline; the ability of EFI, Agfa-Gevaert and Siris to realize the anticipated benefits and synergies; risks associated with integrating the businesses, technologies, operations, employees, systems and customer and supplier relationships of EFI and Agfa DPS; business disruption and the retention of key personnel; and changes in market conditions, customer demand, competition, economic conditions or other factors affecting the industrial inkjet industry and the combined company.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are not guarantees of future performance. Neither EFI, Agfa-Gevaert nor Siris, nor, following completion of the transaction, the combined company, undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise, except as may be required by applicable law.

Attachment

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

EFI and Agfa’s DPS Business to Combine and Form a Global, Full-Service Industrial Inkjet Company

Combination to Create a Broader, More Diversified Business with a Comprehensive Product Portfolio, Expanded Geographic Reach and Enhanced Capabilities to Serve Customers Across Key End Markets

Mortsel, Belgium and Londonderry, N.H. – September 28, 2026 – 7.45 a.m. CET

Electronics for Imaging, Inc. (“EFI”), a leading industrial inkjet business and portfolio company of Siris, and Agfa-Gevaert (“Agfa”) today announced a definitive agreement to combine Agfa’s Digital Printing Solutions business (“Agfa DPS”) with EFI. An affiliate of Siris will hold a 60% interest and Agfa will hold a 40% interest in the jointly held company, which will bring together the operating capabilities of EFI and Agfa DPS under a governance structure whereby Siris and Agfa will act as equal partners.

The agreement follows the global partnership EFI and Agfa established in 2024, which enabled both companies to expand their product offerings through access to complementary technologies, underscoring the value that their respective strengths, application expertise and expanded portfolios could create for customers worldwide.

The combination brings together two leading businesses with specialized technology capabilities and application focus areas to create a scaled industrial inkjet business with breadth across the fastest-growing segments of the industry. Backed by a global service network, the combined company will draw on a broader base of inkjet expertise spanning print engines, inks, software and workflow, shortening the path from development to production for customers.

EFI brings global leadership in industrial inkjet, helping customers accelerate the transition from analog to digital imaging, with particular strength in digital single pass for corrugated packaging, roll-to-roll, hybrid and textile printers through its Nozomi, VUTEK and Reggiani platforms. Agfa DPS is a leading provider of industrial inkjet solutions, with distinct strengths in display graphics, décor and packaging applications. Its recently renewed portfolio includes the Jeti TAURO, Onset PANTHERA and SpeedSet ORCA platforms. Together, EFI and Agfa DPS expect to generate approximately €540 million ($625 million) of revenue in 2026 on a pro forma basis and will serve a diversified base of thousands of customers across more than 100 countries, supported by complementary geographic strengths across North America and Europe and a global sales and service network.

The combined company is expected to have the potential to realize significant synergies over time, driven by enhanced cross-selling opportunities and the benefits of a platform with greater scale, including expanded access to new applications and geographies.

“Today’s announcement reflects our long-term commitment to digital printing and our conviction in the future of the industry,” said Pascal Juéry, CEO of Agfa-Gevaert. “By bringing together Agfa DPS and EFI, we are creating a stronger business with greater scale, broader access and enhanced innovation capabilities. Rather than continue as a standalone business, we are choosing to partner with Siris to unlock the next phase of accelerated growth for our DPS business while maintaining meaningful upside for Agfa’s stakeholders.”

“Since our investment in EFI in 2019, we have supported the company’s evolution into a focused industrial inkjet leader, drawing on our experience helping technology and industrial businesses scale,” said Frank Baker, Co-Founder and Managing Partner, and David Calamai, Managing Director, of Siris. “EFI and Agfa DPS bring together distinct and complementary capabilities, forming a business with the reach and depth to do more for customers across more markets. We look forward to partnering with Agfa to accelerate innovation and expansion for customers worldwide.”

“At Agfa, we believe this combination can help accelerate the adoption of digital printing across the industry,” said Vincent Wille, President of Agfa DPS. “By combining technology leadership, global reach and deep application expertise, we can help our customers achieve new levels of productivity, agility and sustainable growth, enabling them to innovate faster, reduce waste and create lasting value across the entire print ecosystem.”

“Our partnership with Agfa over the past two years has highlighted the strength of our complementary technologies, expertise and teams,” said Frank Pennisi, CEO of EFI. “This combination is a natural next step that allows us to build on that momentum with a broader platform, accelerating innovation and expanding the solutions we can deliver to customers across industrial inkjet.”

The proposed transaction is expected to close by the end of 2026 and is subject to customary employee information and consultation processes, regulatory approvals and closing conditions.

EFI and Siris were advised by DC Advisory, which acted as exclusive financial advisor, and Sidley Austin LLP, which served as legal advisor.

About EFI
EFI™ is a global technology company focused on advancing the transformation from analog to digital imaging. The company has a scalable portfolio of products, solutions, services and support for the manufacturing of signage, packaging, textiles and other industrial printing applications. EFI’s offerings include a wide range of printers, inks, digital front ends and workflow software designed to help customers increase profits, improve productivity and optimize production workflows. www.efi.com

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of €1.1 billion. Through its Digital Printing Solutions (DPS) business unit, Agfa provides cutting-edge inkjet printing solutions—equipment, consumables, software and services—designed for high-quality, efficient production in the sign & display and packaging market, as well as a broad range of industrial markets. www.agfa.com

About Siris
Siris is a leading private equity firm focused on control investments in services businesses that enable transformative technologies to scale. The firm invests in companies that support the underlying infrastructure for these technologies and help enterprises integrate them into critical operational workflows. Based in West Palm Beach, Florida, Siris has deployed more than $9 billion of equity capital since inception. www.siris.com

Contact:
EFI
Holly O’Rourke
Corporate Communications
+1 (603)-475-9244
e-mail: holly.orourke@efi.com

Agfa-Gevaert
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Siris
Kate Kelley / Madeline Jones / Woomi Yun
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
e-mail: Siris-JF@joelefrank.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the proposed combination of Electronics for Imaging, Inc. (“EFI”) and Agfa-Gevaert’s Digital Printing Solutions business (“Agfa DPS”), the anticipated timing of completion of the transaction, including the expectation that it will close by the end of 2026, expected synergies and other benefits of the transaction, and the future operations, business prospects, financial performance and performance of the combined company. Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “will,” “may,” “could,” “should,” “would,” “potential” and similar expressions.

These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results and developments to differ materially. Such risks and uncertainties include, among others, the ability to obtain required regulatory approvals; the completion of customary employee information and consultation processes; the satisfaction of other closing conditions; the possibility that the transaction may be delayed or not completed on the anticipated terms or timeline; the ability of EFI, Agfa-Gevaert and Siris to realize the anticipated benefits and synergies; risks associated with integrating the businesses, technologies, operations, employees, systems and customer and supplier relationships of EFI and Agfa DPS; business disruption and the retention of key personnel; and changes in market conditions, customer demand, competition, economic conditions or other factors affecting the industrial inkjet industry and the combined company.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are not guarantees of future performance. Neither EFI, Agfa-Gevaert nor Siris, nor, following completion of the transaction, the combined company, undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise, except as may be required by applicable law.

Attachment

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Agfa-Gevaert NV extends revolving credit facility

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV has extended its 180 million euro revolving credit facility to August 1, 2030. Under the previous agreement, it was scheduled to mature on August 1, 2028. The facility is used for working capital and general corporate purposes.

The financial covenants included in the facility are now:

Leverage ratio covenant: Net financial debt*/Adj. EBITDA** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): maximum 3.0
Interest coverage ratio covenant: adjusted EBITDA/interest expense** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): minimum 4.0
Liquidity headroom covenant: cash and cash equivalents plus headroom under the Facilities (tested quarterly): minimum 30 million euro

The applicable financial indicators and required covenant levels are disclosed with the quarterly results publication and are tested quarterly or semi-annually following the requirement of the facility agreement.

The facility is now also secured by a pledge of the Agfa HealthCare shares.

The revolving credit facility has been arranged by a club of 4 financial institutions: BNP Paribas Fortis SA/NV, KBC Bank NV, Belfius Bank SA/NV and ING Belgium SA/NV.

*Net financial debt excl IFRS 16: the sum of non-current and current liabilities to banks excluding non-current and current lease liabilities and excluding pension debt, including bank overdrafts minus cash and cash equivalents.
**Adjusted EBITDA: the result from continuing operating activities before depreciation, amortization, restructuring expenses and adjustments.

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

                                       

September 28, 2026 – 7.45 AM CET
Regulated information – Contains inside information

Agfa-Gevaert NV extends revolving credit facility

Mortsel, Belgium – September 28, 2026 – 7.45 a.m. CET

Agfa-Gevaert NV has extended its 180 million euro revolving credit facility to August 1, 2030. Under the previous agreement, it was scheduled to mature on August 1, 2028. The facility is used for working capital and general corporate purposes.

The financial covenants included in the facility are now:

Leverage ratio covenant: Net financial debt*/Adj. EBITDA** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): maximum 3.0
Interest coverage ratio covenant: adjusted EBITDA/interest expense** (calculated excluding IFRS 16 over the last 12 months and tested half-yearly): minimum 4.0
Liquidity headroom covenant: cash and cash equivalents plus headroom under the Facilities (tested quarterly): minimum 30 million euro

The applicable financial indicators and required covenant levels are disclosed with the quarterly results publication and are tested quarterly or semi-annually following the requirement of the facility agreement.

The facility is now also secured by a pledge of the Agfa HealthCare shares.

The revolving credit facility has been arranged by a club of 4 financial institutions: BNP Paribas Fortis SA/NV, KBC Bank NV, Belfius Bank SA/NV and ING Belgium SA/NV.

*Net financial debt excl IFRS 16: the sum of non-current and current liabilities to banks excluding non-current and current lease liabilities and excluding pension debt, including bank overdrafts minus cash and cash equivalents.
**Adjusted EBITDA: the result from continuing operating activities before depreciation, amortization, restructuring expenses and adjustments.

About Agfa-Gevaert
The Agfa-Gevaert Group is a leading company in imaging technology, with nearly 160 years of experience. Agfa develops, manufactures and markets analog and digital systems for the healthcare sector, for the printing industry, for the green hydrogen industry and for specific industrial applications. In 2025, the Group realized a turnover of 1,086 million euro. www.agfa.com

Contact:
Viviane Dictus
Director Corporate Communications
tel. +32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

  Number of
shares
Average purchase
price (DKK)
Transaction
value (DKK)
Accumulated, previous announcement 2,020,805 949.93 1,919,619,024
21 September 2026 10,310 1.112.06 11,465,359
22 September 2026 10,712 1.111.08 11,901,844
23 September 2026 10,162 1.102.36 11,202,133
24 September 2026 10,480 1.099.58 11,523,602
25 September 2026 10,408 1.109.31 11,545,709
Accumulated under the programme 2,072,877 953.87 1,977,257,671

Following settlement of the transactions stated above, Jyske Bank will own a total of 2,072,877 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.56% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
                                                         
Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42

Attachment

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”).

The following transactions have been made under the program:

  Number of
shares
Average purchase
price (DKK)
Transaction
value (DKK)
Accumulated, previous announcement 2,020,805 949.93 1,919,619,024
21 September 2026 10,310 1.112.06 11,465,359
22 September 2026 10,712 1.111.08 11,901,844
23 September 2026 10,162 1.102.36 11,202,133
24 September 2026 10,480 1.099.58 11,523,602
25 September 2026 10,408 1.109.31 11,545,709
Accumulated under the programme 2,072,877 953.87 1,977,257,671

Following settlement of the transactions stated above, Jyske Bank will own a total of 2,072,877 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.56% of the share capital.

Attached to this corporate announcement, aggregated details on the transactions related to the share repurchase programme are shown by venue.
                                                         
Yours faithfully,
Jyske Bank

Contact: Birger Krøgh Nielsen, CFO, tel. +45 25 26 92 42

Attachment

  • €11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026
  • The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection points
  • In this context, publication of first half 2026 financial results is postponed
  • Enrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis now estimated for early-2027 due to a lower number of death events than expected
  • Subcutaneous formulation of lusvertikimab (IL-7R) on track for validation by mid-2027
  • Opportunity to move lusvertikimab into Phase 2 with current IV formulation in chronic pouchitis in 2027


Nantes, France, September 28, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)
, a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today reported its cash position as of June 30, 2026, updated its financial calendar and provided a business update.

“On the operational front, enrolment of Tedopi’s Phase 3 trial ARTEMIA in non-small cell lung cancer is on track. The interim futility analysis for ARTEMIA is event-driven. Deaths across the study have accrued more slowly than originally projected, and the analysis is now expected in early-2027, which is definitely interesting. In parallel, the subcutaneous formulation of lusvertikimab is moving as planned and results should be available by mid-2027 to support pursuing clinical development in ulcerative colitis. We are also very encouraged by our conversations with key opinion leaders to move rapidly into a Phase 2 trial with the current formulation in Chronic Pouchitis, a significant unmet need”, commented Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics. “We have been actively engaging with institutional investors in the United States and in Europe for the past few months, helped by a flexible bridge financing in May, and are confident that the strength of our pipeline provides a solid foundation as we work to secure the financing needed to reach key value inflection points.”

Cash Position as of June 30, 2026

As of June 30, 2026, OSE Immunotherapeutics’ cash position totalled €11.1 million, compared to €17.0 million as of March 31, 2026. 

The Company implemented a flexible bridge equity financing in May 2026 which, in addition to available cash, and based on its current plans, is estimated to be sufficient to fund its operations through December 2026. This cash runway does not include any potential future milestone payments from existing partnerships.

This bridge financing was the first step of a global financing strategy aiming at securing OSE’s 3-year Strategic Plan and the Company continues to actively engage with institutional investors in the United States and in Europe in view to further extend its runway beyond 2026.

In addition, the Company continues to evaluate several complementary options, including a potential new strategic partnership involving one of its proprietary assets, restructuring of its existing debt, and potential milestone payments from current partnerships.

In the context of its ongoing financing efforts, the Company has deferred the publication of its half-year financial statements for 2026 and its Interim Financial Report to a later date.

Pivotal Phase 3 clinical trial ARTEMIA of Tedopi® in second-line non-small cell lung cancer (NSCLC)

Enrolment in the international pivotal Phase 3 clinical trial ARTEMIA evaluating Tedopi® in 363 HLA-A2 positive patients with metastatic NSCLC who have developed secondary resistance to immune checkpoint inhibitors is on track for completion by end of December 2026, as planned.

As per protocol, a futility analysis will be conducted independently by the statisticians of the Independent Data Monitoring Committee (IDMC). This analysis, performed when the trial reaches a predefined number of events, is based on an interim survival analysis and will remain blinded to the Sponsor, Regulatory Authorities, and all Investigators.

Initial assumptions anticipated reaching the required and predefined number of deaths by Q3 2026. While enrolment of the study has progressed according to plan, the trial is showing a lower number of deaths than initially expected, and the Company now anticipates reaching the predefined number of death events by the end of 2026. Consequently, the futility analysis is now expected to take place early 2027.

Other clinical trials evaluating Tedopi® in multiple indications

TEDOVA in ovarian cancer

In May 2026, the Company reported positive topline results from the TEDOVA/GINECO-OV244b/ENGOT-ov58 academic, international, Phase 2 trial sponsored by ARCAGY-GINECO and evaluating Tedopi®, with or without pembrolizumab, as a maintenance treatment in 185 patients with platinum-sensitive recurrent ovarian cancer (PSOC).

The primary endpoint was progression-free survival (PFS) comparing Tedopi® combined with pembrolizumab and the best supportive care. It was met and results showed a statistically significant improvement in PFS for the combination of Tedopi® and pembrolizumab compared to best supportive care (median PFS: 4.1 months vs 2.8 months; HR=0.53; p<0.001). When comparing the two investigational arms, the addition of pembrolizumab to Tedopi® resulted in a 28% reduction in the risk of progression or death (HR=0.72, p=0.074).

These results were presented by principal investigator Alexandra Leary, MD, PhD, at the ASCO 2026 Annual Meeting in May 2026 in Chicago, United States.

Combi-TED in NSCLC

Topline results from the Combi-TED Phase 2 international clinical trial sponsored by FoRT and evaluating Tedopi® in second-line treatment in combination with anti-PD1 or chemotherapy in 105 patients with metastatic NSCLC will be presented by principal investigator Federico Cappuzzo, MD, PhD, at the ESMO 2026 Annual Meeting on October 25, 2026, in Madrid, Spain.

Subcutaneous formulation of lusvertikimab (IL-7R) in inflammatory bowel diseases (IBD)

The subcutaneous formulation of lusvertikimab to be advanced in clinical development was selected and characterized earlier this year. The achieved concentration at 225mg per mL, based on previously evaluated intravenous efficacious doses in Phase 2 of 450mg and 850mg, is potentially compatible with the use of an autoinjector device.

The application for authorization of a Phase I study in healthy volunteers is currently being prepared with a submission scheduled by the end of 2026, with results expected by mid-2027.

ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is listed on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on LinkedIn.

Contacts

OSE Immunotherapeutics: investors@ose-immuno.com

FP2COM (Media Relations): Florence Portejoie: fportejoie@fp2com.fr I +33 6 07 768 283

Astr Partners (Investor Relations):

Europe/UK: Guillaume Cabon: guillaume.cabon@astrpartners.com I +33 6 95 06 92 06

United States: Brian korb: brian.korb@astrpartners.com I +1 917-653-5122

Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. 

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on June 4, 2026, including the annual financial report for the fiscal year 2025, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.